ReForm Therapeutics is a globally focused biopharmaceutical company targeting unmet patient needs

Innovation

Through the application of ReForm Therapeutics’ innovative oral mucosal film technology, the company is developing RFX002, a new oro-mucosal formulation of epinephrine, for the emergency treatment of severe allergic reactions (Type I) to insect stings or bites, foods, drugs, and other allergens.

Commercial Focus

The company has a clear focus to rapidly develop RFX002 and drive significant future revenue through commercial partnerships across global markets.

Our strategy is to develop innovative needle-free formulations to a defined value inflection point and then partner with major pharmaceutical and biotechnology companies; under a revenue-generating licence model ReForm will receive royalties and significant milestone payments.

ReForm is applying our drug delivery technologies and development expertise to multiple well-known therapeutics. Currently ReForm is formulating and testing needle-free formulations to treat organophosphate poisoning, diabetes, dental analgesia and severe ulceration of the mouth.

Needle Free Alternative in Anaphylaxis

What is the problem with auto-injectors?

Auto-injectors have a number of limitations which make them unpopular with patients:

  • Many people suffer from needle phobia
  • Complex administration
  • Poor portability
  • Potential for injury / accidental injections
  • High cost
 

Additional issues with auto-injectors include:

  • Non-tailored dosing (for bodyweight)
  • Needle length (in obese patients / small children)
  • Device failure
  • Limited shelf life
  • High environmental impact

What is ReForm’s solution?

RFX002 is designed to have comparable efficacy to an epinephrine auto-injector.

Once administered, it will dissolve in minutes, having a fast onset of action for emergency treatment. The product will work in a wide range of patients from infants to adults.

The product profile was tested with leading allergologists in Europe and the US.

“I think it will be great. It addresses the difficultly of using an auto-injector and carrying it around – as well as the reluctance to use it and being afraid of injections.” KOL – US

“I think it is an incredibly attractive proposition which could greatly aid compliance.” KOL – EU

Pipeline

ReForm Therapeutics is progressing multiple candidate molecules through development into human trials

Team

ReForm Therapeutics is focused on product development, technical operations and business development: our partners will commercialise RFX002

Projects

Project One

The project “Non-invasive treatment of anaphylaxis - ReForm: the first oral treatment of anaphylaxis with adrenaline,” project proposal number TQ08000002, is co-funded through the Technology Agency of the Czech Republic under the National Recovery Plan from the European Recovery and Resilience Facility.

Project Two

Project number FW09020121 – Development of an effective drug carrier for intranasal administration of organophosphate poisoning, is co-financed with state support from the Technology Agency of the Czech Republic under the TREND Programme.

ReForm Therapeutics Ltd

128-130 City Road

London EC1V 2NX

United Kingdom

 

ReForm Therapeutics CZ s.r.o.

Purkynova 649/127

Brno 61200

Czechia